| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/CIRCHEARTFAILURE.109.930321 |
| P698 | PubMed publication ID | 20498236 |
| P50 | author | Stephen F Vatner | Q96766914 |
| P2093 | author name string | Xin Zhao | |
| Christophe Depre | |||
| Patricio Abarzúa | |||
| Fady I Malik | |||
| You-Tang Shen | |||
| Sunil K Dhar | |||
| David J Morgans | |||
| P433 | issue | 4 | |
| P921 | main subject | heart failure | Q181754 |
| systolic heart failure | Q17326470 | ||
| systole | Q496359 | ||
| P304 | page(s) | 522-527 | |
| P577 | publication date | 2010-05-24 | |
| P1433 | published in | Circulation: Heart Failure | Q2865806 |
| P1476 | title | Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure | |
| P478 | volume | 3 |
| Q37139621 | A myosin activator improves actin assembly and sarcomere function of human-induced pluripotent stem cell-derived cardiomyocytes with a troponin T point mutation |
| Q35315333 | A new model of congestive heart failure in rats |
| Q87990980 | Actomyosin-Mediated Tension Orchestrates Uncoupled Respiration in Adipose Tissues |
| Q85798807 | Alterations in cardiac structure and function in a modified rat model of myocardial hypertrophy |
| Q34070160 | Analytical comparison of natural and pharmaceutical ventricular myosin activators |
| Q38139089 | Antagonist molecules in the treatment of angina |
| Q38939243 | Cardiac Myosin Activators in Systolic Heart Failure: More Friend than Foe? |
| Q37851240 | Cardiac inotropes: current agents and future directions |
| Q33913192 | Cardiac myosin activation part 1: from concept to clinic |
| Q30583292 | Cardiac myosin activation: a potential therapeutic approach for systolic heart failure |
| Q84799461 | Cardiac myosin activation: will theory and practice coincide? |
| Q55025652 | Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil. |
| Q45989354 | Cardiac myosin activators: up and coming. |
| Q64080564 | Cardioprotective Properties of Omecamtiv Mecarbil against Ischemia and Reperfusion Injury |
| Q37402519 | Changes in cardiac structure and function in a modified rat model of myocardial hypertrophy |
| Q39776361 | Characterization of an investigative safety pharmacology model to assess comprehensive cardiac function and structure in chronically instrumented conscious beagle dogs |
| Q44655145 | Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial |
| Q46143451 | Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction |
| Q39155695 | Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin. |
| Q34209528 | Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study |
| Q88599261 | Drugs' development in acute heart failure: what went wrong? |
| Q55286667 | Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats. |
| Q92443501 | Engineered Cardiac Tissues Generated in the Biowire™ II: A Platform for Human-Based Drug Discovery |
| Q37363558 | Focal energy deprivation underlies arrhythmia susceptibility in mice with calcium-sensitized myofilaments |
| Q49907634 | Frequency-dependent effects of omecamtiv mecarbil on cell shortening of isolated canine ventricular cardiomyocytes. |
| Q38780801 | From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure |
| Q38376055 | Heart failure: novel therapeutic approaches |
| Q37258267 | Incorporating development of a patient-reported outcome instrument in a clinical drug development program: examples from a heart failure program |
| Q33894414 | Influence of metabolic dysfunction on cardiac mechanics in decompensated hypertrophy and heart failure |
| Q35265639 | Inhibition of smooth muscle myosin as a novel therapeutic target for hypertension |
| Q38208442 | Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus |
| Q43161763 | Letter by Teerlink et al Regarding Article, "Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity". |
| Q41242943 | Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil |
| Q37920401 | Medical therapy for chronic heart failure |
| Q99546570 | Modulating the tension-time integral of the cardiac twitch prevents dilated cardiomyopathy in murine hearts |
| Q36341946 | Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C |
| Q47572193 | New heart failure pharmacotherapy in clinical trials: a hope in progress |
| Q38594785 | New medical therapies for heart failure |
| Q92069739 | New perspective in heart failure management: could myosin activators be the answer? |
| Q38759494 | New pharmacological approaches in heart failure therapy: developments and possibilities. |
| Q38209074 | Novel drug mechanisms in development for heart failure |
| Q41856322 | Novel strategies for the treatment of heart failure |
| Q46650156 | Omecamtiv Mecarbil Abolishes Length-Mediated Increase in Guinea Pig Cardiac Myofiber Ca2+ Sensitivity |
| Q33768442 | Omecamtiv Mecarbil, a Cardiac Myosin Activator, Increases Ca2+ Sensitivity in Myofilaments With a Dilated Cardiomyopathy Mutant Tropomyosin E54K. |
| Q38639973 | Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure |
| Q57316359 | Omecamtiv mecarbil: a promising new drug in systolic heart failure |
| Q36972415 | Pharmacological Strategies to Retard Cardiovascular Aging |
| Q40964821 | Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure |
| Q30251531 | Potential new drug treatments for congestive heart failure |
| Q58784267 | Prolonged cross-bridge binding triggers muscle dysfunction in a model of myosin-based hypertrophic cardiomyopathy |
| Q38478051 | RNA-sequencing analysis reveals new alterations in cardiomyocyte cytoskeletal genes in patients with heart failure |
| Q36645693 | Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects |
| Q90446344 | Shock - Classification and Pathophysiological Principles of Therapeutics |
| Q37031923 | Structural basis for drug-induced allosteric changes to human β-cardiac myosin motor activity |
| Q27024879 | Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology |
| Q34209536 | The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. |
| Q38870685 | The myosin activator omecamtiv mecarbil: a promising new inotropic agent |
| Q36036237 | The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the rat |
| Q42278153 | The role of super-relaxed myosin in skeletal and cardiac muscle |
| Q30582828 | Thin filament incorporation of an engineered cardiac troponin C variant (L48Q) enhances contractility in intact cardiomyocytes from healthy and infarcted hearts |
| Q37858515 | Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents |
| Q41021204 | Why So Few New Cardiovascular Drugs Translate to the Clinics |
Search more.